The Novartis Malaria Initiative Harvard Case Solution & Analysis

The Novartis Malaria Initiative was devised, as a result of a prior-setting contract with the WHO in 2001, to devise a breakthrough treatment for the malaria-"at no profit"-for public health systems. What had commenced as an outstanding action of corporate responsibility had succeeded beyond any expectations.

In the year 2012, for the 2nd year in a row, Novartis had made and disseminated over 100 million ingredients of the anti-malarial drug Coartem (registered company).) Howeverwith the significantly up-scale quantities came increased prices, bringing into question the sustainability of this system. His aim was to expand accessibility to Coartem in the private sector through a low-margin, high-quantity social business structure to consequentially enable the Malaria Initiative to break even and become fiscally sustainable. Was this the correct strategy?

PUBLICATION DATE: March 25, 2014 PRODUCT #: 314103-HCC-ENG

The Novartis Malaria Initiative Case Study Solution

This is just an excerpt. This case is about STRATEGY about STRATEGY & EXECUTION

Share This

SALE SALE

Save Up To

30%

IN ONLINE CASE STUDY

FOR FREE CASES AND PROJECTS INCLUDING EXCITING DEALS PLEASE REGISTER YOURSELF !!

Register now and save up to 30%.